UNSPSC 51121926: Simendan

This classification denotes a cardiotonic agent with the molecular formula C14H12N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 349552KRHK, chemically known as propanedinitrile, ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)- but generally known as simendan, which bears US NIH Compound Identifier 60867. European Medicines Agency schedules Simendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10525MIG.

UNSPSC 51121926 Simendan, a Commodity code, represents pharmaceutical products and preparations supplied to state and local health agencies, emergency services, and institutional purchasers — grounded in recent solicitations for emergency medications, generic multi-source drugs, and specialized pharmacy programs. State and local governments procuring under this code include municipal fire and rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multi-jurisdictional cooperative purchasing entities (Minnesota's MMCAP, which includes Oregon). Work under the code spans emergency life support medications for first responders, generic pharmaceuticals distributed through authorized wholesalers to public health facilities, and direct-to-manufacturer prescription programs designed to optimize cost and fulfillment for self-insured state employee health plans. Solicitations require compliance with FDA registration, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, OSHA Hazard Communication Standards for Safety Data Sheets, and federal accessibility standards (Section 508 and WCAG 2.2 Level AA).

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (No. 26P00188) in April 2026 for advanced life support medications (epinephrine, labetalol, adenosine, diltiazem) with a due date of April 8, 2026 and an estimated contract value of $40,000, incorporating a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements, signaling the state's intent to explore alternative procurement models. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and to accept a 3 percent administrative fee structure. Vendors supplying under the code must manage expiration tracking (nine-month minimum at acceptance), arrange replacement protocols, and support chargeback systems with wholesaler partners where required.